Abstract
This Practice Point commentary discusses a recent paper by Hoving et al., who compared the cost-effectiveness of continuous intrathecal baclofen infusion (CIBI) with that of 'standard care' in children with cerebral palsy whose abnormal muscle tone was interfering with function and/or quality of life. The current management of severe spasticity and dystonia in cerebral palsy consists of oral medications, botulinum toxin, selective dorsal rhizotomy, orthopedic surgery, and/or CIBI. CIBI is the treatment of choice for patients whose severely abnormal tone is interfering with their care, comfort, and/or quality of life. The added cost of care associated with the use of CIBI for 1 year is nearly twice that of standard care. However, on the basis of their cost-effectiveness analysis, which took into consideration the improvement in quality of life, Hoving et al. concluded that the added expense is cost-effective. Although this prospective study lasted for only 1 year and included only 15 patients, the conclusions are similar to those based on previously published results.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pranzatelli MR (1996) Oral pharmacotherapy for the movement disorders of cerebral palsy. J Child Neurol 11 (Suppl 1): S13–S22
Nemer MR et al. (2006) Validation of a care and comfort hypertonicity questionnaire. Dev Med Child Neurol 48: 181–187
Gooch JL et al. (2004) Care provider assessment of intrathecal baclofen in children. Dev Med Child Neurol 46: 548–552
Hoving MA et al. (2008) Intrathecal baclofen therapy in children with intractable spastic cerebral palsy: a cost-effectiveness analysis. Dev Med Child Neurol 50: 450–455
de Lissovoy G et al. (2007) Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy. J Child Neurol 22: 49–59
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Russman, B. Continuous intrathecal baclofen infusion for intractable spastic cerebral palsy—is it worth it?. Nat Rev Neurol 4, 476–477 (2008). https://doi.org/10.1038/ncpneuro0868
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0868
This article is cited by
-
Intrathecal baclofen therapy for spasticity of cerebral origin—does the position of the intrathecal catheter matter?
Child's Nervous System (2010)